Amicus Therapeutics Executive and Leadership Team

Christopher Agee, the Chief Executive Officer at Amicus Therapeutics, directs the company's overarching strategy and operational execution. Agee guides the organization's mission to discover, develop, and deliver novel medicines for rare metabolic diseases. This leadership involves fostering innovation across research and development, ensuring robust clinical trial progress, and optimizing commercialization efforts to reach patients worldwide. Agee's focus remains on driving sustainable growth and maximizing the impact of Amicus Therapeutics' therapeutic pipeline. The Chief Executive Officer ensures alignment between scientific advancements and business objectives, positioning the company for long-term success in the biotechnology sector. Christopher Agee's strategic vision propels the company's commitment to addressing unmet medical needs.

Tamariah Crowley, the Chairman & Chief Executive Officer at Amicus Therapeutics, provides critical leadership in shaping the company's strategic direction and governance. Crowley oversees the executive team, ensuring the company remains steadfast in its mission to develop and deliver life-changing therapies for rare metabolic diseases. This dual role involves guiding board-level decisions and driving the executive agenda to foster innovation and patient-centricity. Tamariah Crowley's leadership ensures that Amicus Therapeutics maintains its commitment to scientific excellence and ethical business practices. The Chairman & Chief Executive Officer's influence extends across all facets of the organization, from research initiatives to global market access strategies, reinforcing the company's dedication to transforming the lives of patients.

Simon Harford, the Chief Financial Officer at Amicus Therapeutics, oversees all financial planning, reporting, and capital allocation strategies. Harford manages the company's financial health, ensuring robust fiscal management to support the discovery, development, and delivery of novel therapies for rare metabolic diseases. This position involves strategic financial guidance, investor relations, and risk management to sustain the company's growth trajectory. Simon Harford's financial acumen is critical for securing resources and optimizing investments in research and development. The Chief Financial Officer ensures financial transparency and accountability, driving value creation for stakeholders and supporting Amicus Therapeutics' long-term mission to impact patient lives globally.

Steven Tay, the Chief Operating Officer at Amicus Therapeutics, directs the company's global operational functions, ensuring efficient and effective execution of its strategic initiatives. Tay oversees manufacturing, supply chain management, and quality control, guaranteeing the consistent production of high-quality medicines for rare metabolic diseases. This leadership role is vital for scaling operations to meet increasing patient demand and maintaining rigorous compliance standards. Steven Tay's operational expertise underpins the company's ability to deliver on its patient commitments. The Chief Operating Officer ensures that all operational processes align with Amicus Therapeutics' mission, driving excellence in product delivery and fostering a culture of continuous improvement across all manufacturing and logistical activities.

Sam Pierre-Louis, the Chief Information Officer at Amicus Therapeutics, architects and manages the company's technology infrastructure and digital strategy. Pierre-Louis oversees the implementation of advanced IT solutions that support research, development, and commercial operations, ensuring data integrity and cybersecurity across the organization. This role is crucial for enabling seamless collaboration among global teams and facilitating the efficient delivery of therapies to patients with rare metabolic diseases. Sam Pierre-Louis drives technological innovation, enhancing operational efficiency and supporting the company's growth objectives. The Chief Information Officer ensures that Amicus Therapeutics leverages cutting-edge technology to advance its mission and maintain a competitive edge in the biotechnology landscape.

David Clark, the Chief People Officer at Amicus Therapeutics, leads the human resources function, focusing on talent acquisition, development, and fostering a positive organizational culture. Clark is responsible for building and retaining a high-performing team dedicated to the company's mission of developing treatments for rare metabolic diseases. This role involves implementing strategic HR initiatives that support employee engagement, diversity, and inclusion across global operations. David Clark cultivates an environment where innovation thrives and employees are empowered to contribute to patient well-being. The Chief People Officer ensures that Amicus Therapeutics attracts and nurtures the talent necessary to achieve its ambitious goals in biotechnology and patient care.

Ellen Rosenberg, the Chief Legal Officer at Amicus Therapeutics, provides comprehensive legal counsel and oversees all legal affairs for the organization. Rosenberg ensures compliance with regulatory requirements, manages intellectual property, and advises on corporate governance matters critical to the development and commercialization of therapies for rare metabolic diseases. This leadership position safeguards the company's interests and supports its strategic objectives through expert legal guidance. Ellen Rosenberg's legal expertise is fundamental to navigating the complex regulatory landscape of the pharmaceutical industry. The Chief Legal Officer plays a pivotal role in mitigating risks and ensuring that Amicus Therapeutics operates with the highest standards of integrity and legal compliance.